Lixte Biotechnology Holdings, Inc.

NASDAQ:LIXT

Biotechnology

Healthcare
$7.21 +6.61%

+$0.46 today

Market cap
$89.11M
Beta
1.05
P/E (TTM)
-11.1
EPS (TTM)
-$0.67
52W Low $0.68High $7.78

Volume 0.61M

Average 0.12M

LIXT Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Lixte Biotechnology Holdings, Inc.NASDAQ: LIXT

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization outflow grows to $0

Q1 FY2026 depreciation & amortization was $0, compared with $0 a year earlier. Trailing-twelve-month depreciation & amortization was $0.

Context

  • Depreciation & amortization increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly depreciation & amortization holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Depreciation & Amortization vs competitors

How LIXT compares with its peers on the latest reported figures

  • LIXT's LTM Mar 2026 depreciation & amortization of $0 is the smallest of the 2 companies compared; the peer median is $570.24K.
LIXT Competitors Peer median
Depreciation & Amortization for LIXT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CINGCingulate Inc.LTM Mar 2026$570.24K -99.9%+11.1%—
LIXTLixte Biotechnology Holdings, Inc.LTM Mar 2026$0 ———
Peer median (excluding LIXT) $570.24K-99.9%+11.1%—

Competitors are the stored peer set for LIXT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(6.73M)(6.31M)(5.09M)(3.59M)(6.01M)
Depreciation & Amortization00000
Deferred Income Tax00000
Stock-Based Compensation2.6M1.55M0418.42K1.56M
Change in Working Capital(13.44K)154.76K20.56K3.01K412.88K
Accounts Receivables00000
Inventory00000
Accounts Payables35.67K2.32K(73.98K)(73.55K)0
Other Working Capital(49.11K)152.44K94.54K76.56K412.88K
Other Non-Cash Items00773.2K0966.09K
Operating Cash Flow(4.14M)(4.61M)(4.29M)(3.16M)(3.07M)
Capital Expenditures0(3)0(4)0
Acquisitions (Net)00000
Purchases of Investments0000(3.08M)
Sales of Investments00000
Other Investing Activities0000(95.1K)
Investing Cash Flow0000(3.17M)
Debt Repayment00000
Common Stock Issued3.69M5.14M3.14M010.31M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities207.63K06.32K00
Financing Cash Flow3.9M5.14M3.14M010.31M
Effect of Forex Changes00000
Net Change in Cash(245.52K)529.65K(1.15M)(3.16M)4.07M
Free Cash Flow(4.14M)(4.61M)(4.29M)(3.16M)(3.07M)

Lixte Biotechnology Holdings, Inc.

NASDAQ:LIXT

Intrinsic Alpha fair value

Locked

Current Price

$7.21

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.